Clinical trials: Advanced Solid Tumors (Phase 1)
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Neoplasms
Rogaratinib (BAY1163877) in Chinese Patients
This study is planned to determine the safety and tolerability of rogaratinib in Chinese patients with fibroblast growth factor receptor (FGFR)-positive refractory, locally advanced, or metastatic solid tumors and to characterize…
- Trial name
- NCT03788603
- Testing
- Rogaratinib (BAY1163877)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Bayer
Tumors
Study of BMS-663513 in Patients With Advanced Cancer
This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
- Trial name
- NCT00309023
- Testing
- BMS-663513
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
- Trial name
- NCT00374660
- Testing
- Oxaliplatin, Irofulven
- Where
- 7 sites in France
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Neoplasms
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no…
- Trial name
- NCT02025803
- Testing
- TAS-114/capecitabine
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Taiho Oncology, Inc.
Tumor, Solid, Cancer, Metastatic
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with…
- Conditions
- Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
- Trial name
- NCT03491631
- Testing
- SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms, Carcinoma, Hepatocellular
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of…
- Conditions
- Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
- Trial name
- NCT06687941
- Testing
- AST-201
- Where
- 4 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Aptamer Sciences, Inc.
Patients With Advanced Solid Tumors
BAT7104 in Patients With Advanced Solid Tumours
This is a prospective multi-centre, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours in Australia.
- Trial name
- NCT05200013
- Testing
- BAT7104
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Bio-Thera Solutions
Advanced Solid Tumors, Neoplasms
A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer
- Trial name
- CVX-045-101 (NCT00879554)
- Testing
- CVX-045
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Solid Tumor, Adult
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Trial name
- NCT04219254
- Testing
- BI1206
- Where
- 26 sites in United States, Georgia and 5 more
- Volunteers
- 197 people
- Sponsor
- BioInvent International AB
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
This example planning study proposes a phase 1/2 evaluation of an allogeneic, cord-blood-derived dual-target CAR-NK product directed against CLDN18.2 and HER2 (ERBB2) in adults with unresectable or metastatic gastric or…
- Trial name
- DUET-GEJ (NCT07551362)
- Testing
- EB-DT-CAR-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Solid Tumor
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.
- Trial name
- NCT01363024
- Testing
- MFGR1877S
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Advanced Malignant Solid Tumors
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.
- Trial name
- NCT01128842
- Testing
- Neratinib, Capecitabine
- Where
- 2 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Puma Biotechnology, Inc.
Locally Advanced Solid Tumor
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of…
- Trial name
- NCT04084366
- Testing
- OBI-999
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- OBI Pharma, Inc
Advanced Cancer, Refractory Cancer
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors.
- Trial name
- NCT00551850
- Testing
- AV-412
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Cancer, Advanced Solid Tumor
A Study in Patients With Advanced Cancers
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05320588
- Testing
- BIO-106, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 332 people
- Sponsor
- BiOneCure Therapeutics Inc.
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of fully human anti-VEGFR2 monoclonal antibody, HLX06, in patients with advanced or metastatic tumors refractory to…
- Trial name
- NCT03494231
- Testing
- HLX06
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Henlix, Inc
Solid Tumors, Lymphomas
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. This is a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT02740270
- Testing
- GWN323, PDR001
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.